It would be more meaningful to have a discussion about context and why a price would go up or down instead of depending on the 'tried-and-true' gap will be filled because it will.
That isn't much different than saying the price will rise because there are important catalysts in Sept.
I think the market is seeing that CLSN is under-valued, with respect to some peers in Biotech, eg KERX OREX.
If something is viewed as being under-valued, it has a difficult time selling off big, especially when time is getting short for potential big breaking news. People will be there to catch the sell-off, if it comes, more-so than they would have several months ago.
You say you won't buy in until 3.60, you might be right, we shall see, I'll buy some there with you.
Market Data 
Markets 
AI
